# MDT Discussion Log — 2026-01-21_08-33-54
Generated automatically by MDT Pipeline.



## CASE (structured JSON)

```
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}
```


## FINAL MDT OUTPUT

```
Final Assessment:  
Recurrent platinum-resistant ovarian clear cell carcinoma with confirmed progression in liver, presacral, and new right iliac bone sites [@2022-12-29 | MR], [@2022-12-29 | CT]; BRCA1/2 and HRD negative [@OH2203828 | Genomics]; anemia present (HGB 74 g/L [@20230103|5600862 | LAB]); FOLR1, TMB, PD-L1, and HER2 status unknown.  

Core Treatment Strategy:  
- Confirm disease progression and platinum-resistant status per imaging and tumor markers [@2022-12-29 | MR], [@2022-12-29 | CT], [@2022-12-29 | LAB]  
- Prioritize correction of anemia before systemic therapy initiation [@20230103|5600862 | LAB]  
- Obtain FDG-PET to clarify splenic lesion and metastatic burden per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  
- Pursue non-platinum-based regimens or clinical trials given HRD-negative status [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  

Change Triggers:  
- If PET confirms bone metastases, initiate skeletal protection per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42]  
- If FOLR1-positive, consider FRα-targeted therapy in trial context; if HER2+, re-evaluate trial eligibility

---
## References

### Guidelines

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
  Document: nccn_ovariancancer_v3_2025__v00000000, Page 13
  Content: the most recent available tumor tissue. Tumor molecular...

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42]
  [Not cached]

### Literature

### Clinical Trials

### Clinical Reports

[@2022-12-29 | MR]
  MR ID: 2022-12-29

[@2022-12-29 | CT]
  CT ID: 2022-12-29

[@OH2203828 | Genomics]
  Genomics ID: OH2203828 | Date: 2022-04-18
  Content: ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1...

[@20230103|5600862 | LAB]
  LAB ID: 20230103|5600862 | Date: 2023-01-03
  Content: 中性粒细胞% 76.5 % (GRAN) PLT分布宽度 12 % (PDW) 嗜碱性细胞数 0.01 *10^9/L...

[@2022-12-29 | LAB]
  LAB ID: 2022-12-29

```


## PIPELINE FLOW (Mermaid)

```mermaid
flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]
```


## TRACE EVENTS (Structured)

```json
[
  {
    "ts": "2026-01-21T08:31:16.626145",
    "event": "pipeline_start",
    "payload": {
      "visit_time": "2023-01-03 08:53:29.260000",
      "meta_info": "340123197709263626"
    }
  },
  {
    "ts": "2026-01-21T08:31:16.626562",
    "event": "case_fingerprint",
    "payload": {
      "case_fingerprint": "2a31f255c155"
    }
  },
  {
    "ts": "2026-01-21T08:31:16.883109",
    "event": "reports_loaded",
    "payload": {
      "lab_n": 92,
      "img_n": 10,
      "path_n": 0,
      "mut_n": 1,
      "cutoff_dt": "2023-01-04 08:53:29"
    }
  },
  {
    "ts": "2026-01-21T08:31:30.985460",
    "event": "reports_selected",
    "payload": {
      "lab": {
        "chair": [
          "20230103|10100203|2023-01-03",
          "20230103|17902116|2023-01-03",
          "20230103|5600862|2023-01-03"
        ],
        "oncologist": [
          "20230103|10100203|2023-01-03",
          "20230103|17902116|2023-01-03",
          "20230103|5600862|2023-01-03"
        ],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "imaging": {
        "chair": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "oncologist": [],
        "radiologist": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "pathologist": [],
        "nuclear": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ]
      },
      "pathology": {
        "chair": [],
        "oncologist": [],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "mutation": {
        "chair": [
          "OH2203828|2022-04-18"
        ],
        "oncologist": [
          "OH2203828|2022-04-18"
        ],
        "radiologist": [],
        "pathologist": [
          "OH2203828|2022-04-18"
        ],
        "nuclear": []
      }
    }
  },
  {
    "ts": "2026-01-21T08:31:30.990009",
    "event": "rag_key_facts",
    "payload": {
      "facts": "DIAGNOSIS: primary=卵巢癌复发; histology=透明细胞癌; 肠壁全层见高级别腺癌; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"
    }
  },
  {
    "ts": "2026-01-21T08:31:44.405077",
    "event": "rag_query",
    "payload": {
      "query": "clear; histology: clear cell carcinoma"
    }
  },
  {
    "ts": "2026-01-21T08:31:44.405082",
    "event": "rag_hits",
    "payload": {
      "source": "guideline",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T08:31:44.405083",
    "event": "rag_hits",
    "payload": {
      "source": "pubmed",
      "topk": 5,
      "n": 0
    }
  },
  {
    "ts": "2026-01-21T08:31:44.405084",
    "event": "rag_hits_merged",
    "payload": {
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T08:31:51.356563",
    "event": "mdt_discussion_start",
    "payload": {
      "num_rounds": 2,
      "num_turns": 2
    }
  },
  {
    "ts": "2026-01-21T08:31:51.356601",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "chair",
      "order": 1
    }
  },
  {
    "ts": "2026-01-21T08:31:54.789907",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "chair",
      "chars": 12
    }
  },
  {
    "ts": "2026-01-21T08:31:54.789994",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "oncologist",
      "order": 2
    }
  },
  {
    "ts": "2026-01-21T08:31:57.520098",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "oncologist",
      "chars": 402
    }
  },
  {
    "ts": "2026-01-21T08:31:57.520151",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "radiologist",
      "order": 3
    }
  },
  {
    "ts": "2026-01-21T08:32:00.026174",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "radiologist",
      "chars": 404
    }
  },
  {
    "ts": "2026-01-21T08:32:00.026204",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "pathologist",
      "order": 4
    }
  },
  {
    "ts": "2026-01-21T08:32:05.331124",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "pathologist",
      "chars": 317
    }
  },
  {
    "ts": "2026-01-21T08:32:05.331194",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "nuclear",
      "order": 5
    }
  },
  {
    "ts": "2026-01-21T08:32:07.290924",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "nuclear",
      "chars": 21
    }
  },
  {
    "ts": "2026-01-21T08:33:40.272511",
    "event": "mdt_discussion_end",
    "payload": {
      "merged_chars": 2258
    }
  },
  {
    "ts": "2026-01-21T08:33:40.274802",
    "event": "trial_matching_start",
    "payload": {
      "trials_json_path": "files/all_trials_filtered.json"
    }
  },
  {
    "ts": "2026-01-21T08:33:42.144004",
    "event": "trial_matching_end",
    "payload": {
      "recommended": false
    }
  },
  {
    "ts": "2026-01-21T08:33:42.144027",
    "event": "final_output_start",
    "payload": {}
  },
  {
    "ts": "2026-01-21T08:33:54.162626",
    "event": "final_output_end",
    "payload": {
      "final_output_chars": 1929
    }
  }
]
```


## INITIAL EXPERT OPINIONS


## chair

```
Additionally
```


## oncologist

```
- Recurrent clear cell carcinoma with rising CA125/CA19-9; imaging confirms liver and bone metastases [@2022-12-29 | CT].  
- BRCA1/2 and HRD negative per comprehensive NGS; molecular profile supports non-homologous recombination repair deficiency [@OH2203828 | Genomics].  
- Current anemia (HGB 74 g/L) requires evaluation; recent labs confirm stable renal/hepatic function [@20230103|5600862 | LAB].
```


## radiologist

```
- Presacral mass increased to 53×44 mm with heterogeneous enhancement and new right iliac bone nodule [@2022-12-29 | MR]  
- Multiple hepatic metastases progressed in size and number; splenic hypodensity suggests possible infarct [@2022-12-29 | CT]  
- Peritoneal and sacral involvement noted; surveillance imaging supports disease progression [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
```


## pathologist

```
- Ovarian origin favored: PAX8+, HNF1B+, WT1–, NapsinA focal+ supports clear cell carcinoma [@OH2203828 | Genomics]  
- BRCA1/2 and HRD status negative per comprehensive NGS [@OH2203828 | Genomics]  
- Molecular tumor profiling recommended to guide therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
```


## nuclear

```
Unknown/needs update.
```


## MERGED SUMMARY (Assistant)

```
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising CA125/CA19-9.  
- Progressive disease: enlarging presacral mass (53×44 mm), new right iliac bone metastasis, multiple progressing hepatic lesions, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; classified as platinum-resistant recurrence (progression within 6 months).  
- Anemia present (HGB 74 g/L); stable renal/hepatic function; symptomatic management prioritized prior to next-line therapy.  
- Splenic hypodensity noted on CT; metabolic characterization pending to rule out metastasis.  
- FDG-PET recommended for accurate staging and assessment of metabolic burden.

**Controversies:**  
- Optimal systemic regimen in HRD-negative, platinum-resistant clear cell carcinoma with limited response to standard chemotherapy; role of non-platinum regimens, immunotherapy (e.g., anti-PD-1), or clinical trials remains uncertain.  
- Clinical significance of splenic lesion: indeterminate for metastasis vs. benign infarct—impacts staging and treatment decisions.

**Missing Info:**  
- FDG-PET results pending; required to clarify splenic lesion and full metastatic extent.  
- FOLR1, TMB, and PD-L1 status unknown—pending update from tissue profiling (OH2203828 | Genomics).  
- Performance status, symptom burden, and transfusion dependence not documented.  
- Prior treatment details: platinum-free interval, prior lines of therapy, and response data not fully specified.

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and biomarkers; classify as platinum-resistant recurrence.  
- Prioritize supportive care: evaluate and manage anemia (consider transfusion) before initiating systemic therapy.  
- Perform FDG-PET for metabolic staging: clarify splenic lesion, assess bone and nodal involvement, and guide therapy.  
- Discuss non-platinum-based regimens or clinical trial options given HRD-negative and platinum-resistant status.  
- Consider skeletal-targeted agents (e.g., denosumab or bisphosphonates) pending confirmation of bone metastases.  
- Await updated molecular profiling (FOLR1, TMB, PD-L1) to explore immunotherapy or targeted therapy eligibility.
```


## INTERACTION LOG (Round × Turn)

### Round 1

#### Turn 1
- **chair → oncologist:** BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].
- **chair → radiologist:** New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies.
- **chair → pathologist:** Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.
- **oncologist → chair:** Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB].
- **radiologist → chair:** Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification.
- **nuclear → chair:** PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].


## FINAL REFINED PLANS (per Round)

### Round 1


## chair

```
- Confirm progression in platinum-resistant ovarian clear cell carcinoma with rising CA125 [@2022-12-29 | LAB] and new metastases on [@2022-12-29 | MR], [@2022-12-29 | CT]  
- Prioritize symptomatic and supportive management given HGB 74 g/L [@20230103|5600862 | LAB] before next systemic regimen  
- Pursue FDG-PET or confirmatory imaging for indeterminate splenic lesion [@2022-12-29 | CT] per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13] for accurate staging
```


## oncologist

```
- Proceed with platinum-resistant recurrence regimen given HRD-negative status and progression within 6 months [@OH2203828 | Genomics; @guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].  
- Address symptomatic anemia (HGB 74 g/L) prior to systemic therapy; assess transfusion need [@20230103|5600862 | LAB].  
- Obtain PET imaging to clarify splenic lesion and metastatic burden; guide skeletal protection if confirmed [@2022-12-29 | CT].
```


## radiologist

```
- Progressive presacral and new right iliac bone lesions confirmed on MRI [@2022-12-29 | MR]  
- Hepatic metastases increased in number and size; splenic hypodensity requires PET correlation [@2022-12-29 | CT]  
- Disease progression evident; consider staging with FDG-PET per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
```


## pathologist

```
- Recurrent clear cell carcinoma confirmed: PAX8+, HNF1B+, WT1– [@OH2203828 | Genomics]  
- BRCA1/2 and HRD negative; consider non-platinum regimens or trials [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  
- FOLR1, TMB, and PD-L1 status unknown; pending update from tissue profiling [@OH2203828 | Genomics]
```


## nuclear

```
- Progressive presacral and hepatic metastases confirmed on recent MR/CT [@2022-12-29 | MR], [@2022-12-29 | CT]; metabolic characterization via PET pending.  
- Bone metastasis suspected with new iliac lesion [@2022-12-29 | MR]; consider skeletal-targeted agents per guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42].  
- Splenic hypodensity indeterminate for metastasis [@2022-12-29 | CT]; recommend FDG-PET to clarify metabolic activity.
```


## RAW AGENT LOGS

### chair
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Additionally
  
  *(2026-01-21T08:31:54.789876)*

- **User:** ROLE: chair. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

Allowed targets: [oncologist,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"oncologist","message":"BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].","why":"missing"},{"target":"radiologist","message":"New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies.","why":"new"},{"target":"pathologist","message":"Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.","why":"missing"}]}
  
  *(2026-01-21T08:32:24.559986)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

[RECENT_DELTAS]
[R1T1 DELTA] gist(new): New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair->pathologist(missing): Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue. | oncologist->chair(safety): Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB]. | radiologist->chair(unspecified): Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification. | nuclear->chair(unspecified): PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]. | chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Confirm progression in platinum-resistant ovarian clear cell carcinoma with rising CA125 [@2022-12-29 | LAB] and new metastases on [@2022-12-29 | MR], [@2022-12-29 | CT]  
- Prioritize symptomatic and supportive management given HGB 74 g/L [@20230103|5600862 | LAB] before next systemic regimen  
- Pursue FDG-PET or confirmatory imaging for indeterminate splenic lesion [@2022-12-29 | CT] per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13] for accurate staging
  
  *(2026-01-21T08:32:38.569671)*

- **User:** 
As the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.
Based on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.

# MDT DISCUSSION SUMMARY
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising CA125/CA19-9.  
- Progressive disease: enlarging presacral mass (53×44 mm), new right iliac bone metastasis, multiple progressing hepatic lesions, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; classified as platinum-resistant recurrence (progression within 6 months).  
- Anemia present (HGB 74 g/L); stable renal/hepatic function; symptomatic management prioritized prior to next-line therapy.  
- Splenic hypodensity noted on CT; metabolic characterization pending to rule out metastasis.  
- FDG-PET recommended for accurate staging and assessment of metabolic burden.

**Controversies:**  
- Optimal systemic regimen in HRD-negative, platinum-resistant clear cell carcinoma with limited response to standard chemotherapy; role of non-platinum regimens, immunotherapy (e.g., anti-PD-1), or clinical trials remains uncertain.  
- Clinical significance of splenic lesion: indeterminate for metastasis vs. benign infarct—impacts staging and treatment decisions.

**Missing Info:**  
- FDG-PET results pending; required to clarify splenic lesion and full metastatic extent.  
- FOLR1, TMB, and PD-L1 status unknown—pending update from tissue profiling (OH2203828 | Genomics).  
- Performance status, symptom burden, and transfusion dependence not documented.  
- Prior treatment details: platinum-free interval, prior lines of therapy, and response data not fully specified.

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and biomarkers; classify as platinum-resistant recurrence.  
- Prioritize supportive care: evaluate and manage anemia (consider transfusion) before initiating systemic therapy.  
- Perform FDG-PET for metabolic staging: clarify splenic lesion, assess bone and nodal involvement, and guide therapy.  
- Discuss non-platinum-based regimens or clinical trial options given HRD-negative and platinum-resistant status.  
- Consider skeletal-targeted agents (e.g., denosumab or bisphosphonates) pending confirmation of bone metastases.  
- Await updated molecular profiling (FOLR1, TMB, PD-L1) to explore immunotherapy or targeted therapy eligibility.

# INITIAL EXPERT OPINIONS
- chair: Additionally
- oncologist: - Recurrent clear cell carcinoma with rising CA125/CA19-9; imaging confirms liver and bone metastases [@2022-12-29 | CT].  
- BRCA1/2 and HRD negative per comprehensive NGS; molecular profile supports
- radiologist: - Presacral mass increased to 53×44 mm with heterogeneous enhancement and new right iliac bone nodule [@2022-12-29 | MR]  
- Multiple hepatic metastases progressed in size and number; splenic hypodens
- pathologist: - Ovarian origin favored: PAX8+, HNF1B+, WT1–, NapsinA focal+ supports clear cell carcinoma [@OH2203828 | Genomics]  
- BRCA1/2 and HRD status negative per comprehensive NGS [@OH2203828 | Genomics]  

- nuclear: Unknown/needs update.

# DISCUSSION INTERACTIONS
Round 1: R1T1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternativ | R1T1: chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bon | R1T1: chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if ad | R1T1: oncologist→chair: Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active m | R1T1: radiologist→chair: Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommen



# FINAL REFINED PLANS (All experts, all rounds)
{
  "Round 1": {
    "chair": "- Confirm progression in platinum-resistant ovarian clear cell carcinoma with rising CA125 [@2022-12-29 | LAB] and new metastases on [@2022-12-29 | MR], [@2022-12-29 | CT]  \n- Prioritize symptomatic and supportive management given HGB 74 g/L [@20230103|5600862 | LAB] before next systemic regimen  \n- Pursue FDG-PET or confirmatory imaging for indeterminate splenic lesion [@2022-12-29 | CT] per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13] for accurate staging",
    "oncologist": "- Proceed with platinum-resistant recurrence regimen given HRD-negative status and progression within 6 months [@OH2203828 | Genomics; @guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].  \n- Address symptomatic anemia (HGB 74 g/L) prior to systemic therapy; assess transfusion need [@20230103|5600862 | LAB].  \n- Obtain PET imaging to clarify splenic lesion and metastatic burden; guide skeletal protection if confirmed [@2022-12-29 | CT].",
    "radiologist": "- Progressive presacral and new right iliac bone lesions confirmed on MRI [@2022-12-29 | MR]  \n- Hepatic metastases increased in number and size; splenic hypodensity requires PET correlation [@2022-12-29 | CT]  \n- Disease progression evident; consider staging with FDG-PET per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]",
    "pathologist": "- Recurrent clear cell carcinoma confirmed: PAX8+, HNF1B+, WT1– [@OH2203828 | Genomics]  \n- BRCA1/2 and HRD negative; consider non-platinum regimens or trials [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  \n- FOLR1, TMB, and PD-L1 status unknown; pending update from tissue profiling [@OH2203828 | Genomics]",
    "nuclear": "- Progressive presacral and hepatic metastases confirmed on recent MR/CT [@2022-12-29 | MR], [@2022-12-29 | CT]; metabolic characterization via PET pending.  \n- Bone metastasis suspected with new iliac lesion [@2022-12-29 | MR]; consider skeletal-targeted agents per guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42].  \n- Splenic hypodensity indeterminate for metastasis [@2022-12-29 | CT]; recommend FDG-PET to clarify metabolic activity."
  }
}

# CLINICAL TRIAL RECOMMENDATION (from assistant)
Trial Recommendation:
- id: None
- name: None
- Reason: HER2 status is unknown and required for all potentially applicable trials.
- Missing eligibility confirmations (0-2 items):
  - HER2 expression status (IHC or mutation)
  - Confirmation of treatment line beyond platinum resistance

STRICT RULES:
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.
- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).
- If experts disagree, pick the safest plan and state the key uncertainty.
- You MUST consider the MDT discussion summary and interactions above when making your decision.

# Response Format
Final Assessment:
<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>

Core Treatment Strategy:
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >

Change Triggers:
- < ≤20 words "if X, then adjust management from A to B" >
- < ≤20 words "if X, then adjust management from A to B" >

  
  **Assistant:** Final Assessment:  
Recurrent platinum-resistant ovarian clear cell carcinoma with confirmed progression in liver, presacral, and new right iliac bone sites [@2022-12-29 | MR], [@2022-12-29 | CT]; BRCA1/2 and HRD negative [@OH2203828 | Genomics]; anemia present (HGB 74 g/L [@20230103|5600862 | LAB]); FOLR1, TMB, PD-L1, and HER2 status unknown.  

Core Treatment Strategy:  
- Confirm disease progression and platinum-resistant status per imaging and tumor markers [@2022-12-29 | MR], [@2022-12-29 | CT], [@2022-12-29 | LAB]  
- Prioritize correction of anemia before systemic therapy initiation [@20230103|5600862 | LAB]  
- Obtain FDG-PET to clarify splenic lesion and metastatic burden per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  
- Pursue non-platinum-based regimens or clinical trials given HRD-negative status [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  

Change Triggers:  
- If PET confirms bone metastases, initiate skeletal protection per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42]  
- If FOLR1-positive, consider FRα-targeted therapy in trial context; if HER2+, re-evaluate trial eligibility
  
  *(2026-01-21T08:33:54.160013)*


### oncologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Recurrent clear cell carcinoma with rising CA125/CA19-9; imaging confirms liver and bone metastases [@2022-12-29 | CT].  
- BRCA1/2 and HRD negative per comprehensive NGS; molecular profile supports non-homologous recombination repair deficiency [@OH2203828 | Genomics].  
- Current anemia (HGB 74 g/L) requires evaluation; recent labs confirm stable renal/hepatic function [@20230103|5600862 | LAB].
  
  *(2026-01-21T08:31:57.520081)*

- **User:** ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

Allowed targets: [chair,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB].","why":"safety"}]}
  
  *(2026-01-21T08:32:25.851681)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

[RECENT_DELTAS]
[R1T1 DELTA] gist(new): New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair->pathologist(missing): Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue. | oncologist->chair(safety): Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB]. | radiologist->chair(unspecified): Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification. | nuclear->chair(unspecified): PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]. | chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Proceed with platinum-resistant recurrence regimen given HRD-negative status and progression within 6 months [@OH2203828 | Genomics; @guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].  
- Address symptomatic anemia (HGB 74 g/L) prior to systemic therapy; assess transfusion need [@20230103|5600862 | LAB].  
- Obtain PET imaging to clarify splenic lesion and metastatic burden; guide skeletal protection if confirmed [@2022-12-29 | CT].
  
  *(2026-01-21T08:32:48.375416)*


### radiologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Presacral mass increased to 53×44 mm with heterogeneous enhancement and new right iliac bone nodule [@2022-12-29 | MR]  
- Multiple hepatic metastases progressed in size and number; splenic hypodensity suggests possible infarct [@2022-12-29 | CT]  
- Peritoneal and sacral involvement noted; surveillance imaging supports disease progression [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
  
  *(2026-01-21T08:32:00.026167)*

- **User:** ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

Allowed targets: [chair,oncologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification.","why":"missing-critical"}]}
  
  *(2026-01-21T08:32:27.332389)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

[RECENT_DELTAS]
[R1T1 DELTA] gist(new): New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair->pathologist(missing): Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue. | oncologist->chair(safety): Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB]. | radiologist->chair(unspecified): Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification. | nuclear->chair(unspecified): PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]. | chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Progressive presacral and new right iliac bone lesions confirmed on MRI [@2022-12-29 | MR]  
- Hepatic metastases increased in number and size; splenic hypodensity requires PET correlation [@2022-12-29 | CT]  
- Disease progression evident; consider staging with FDG-PET per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
  
  *(2026-01-21T08:33:06.365778)*


### pathologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** - Ovarian origin favored: PAX8+, HNF1B+, WT1–, NapsinA focal+ supports clear cell carcinoma [@OH2203828 | Genomics]  
- BRCA1/2 and HRD status negative per comprehensive NGS [@OH2203828 | Genomics]  
- Molecular tumor profiling recommended to guide therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]
  
  *(2026-01-21T08:32:05.331103)*

- **User:** ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

Allowed targets: [chair,oncologist,radiologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"no","messages":[]}
  
  *(2026-01-21T08:32:28.080083)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

[RECENT_DELTAS]
[R1T1 DELTA] gist(new): New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair->pathologist(missing): Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue. | oncologist->chair(safety): Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB]. | radiologist->chair(unspecified): Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification. | nuclear->chair(unspecified): PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]. | chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Recurrent clear cell carcinoma confirmed: PAX8+, HNF1B+, WT1– [@OH2203828 | Genomics]  
- BRCA1/2 and HRD negative; consider non-platinum regimens or trials [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  
- FOLR1, TMB, and PD-L1 status unknown; pending update from tissue profiling [@OH2203828 | Genomics]
  
  *(2026-01-21T08:33:09.048175)*


### nuclear
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Unknown/needs update.
  
  *(2026-01-21T08:32:07.290897)*

- **User:** ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

Allowed targets: [chair,oncologist,radiologist,pathologist]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].","why":"missing-critical"}]}
  
  *(2026-01-21T08:32:29.690933)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

[RECENT_DELTAS]
[R1T1 DELTA] gist(new): New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair->pathologist(missing): Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue. | oncologist->chair(safety): Anemia (HGB 74 g/L) requires urgent evaluation before systemic therapy; recent CBC supports active management [@20230103|5600862 | LAB]. | radiologist->chair(unspecified): Splenic hypodensity noted on CT; indeterminate if infarct or metastasis [@2022-12-29 | CT]. Recommend PET or follow-up imaging for clarification. | nuclear->chair(unspecified): PET metabolic findings are critical for staging but missing; current assessment relies on MR/CT without functional imaging [@2022-12-29 | MR], [@2022-12-29 | CT].

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: BRCA1/2 negative and HRD negative per comprehensive NGS [@OH2203828 | Genomics]; consider alternative non-platinum regimens or clinical trials given platinum-resistant clear cell histology [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]. | chair→radiologist: New right iliac bone nodule and progressive presacral mass on [@2022-12-29 | MR]; correlate with bone metastasis and consider skeletal protection strategies. | chair→pathologist: Clear cell carcinoma confirmed by PAX8+, HNF1B+, WT1- immunoprofile; update molecular findings if additional FOLR1 or TMB data are available from prior tissue.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** - Progressive presacral and hepatic metastases confirmed on recent MR/CT [@2022-12-29 | MR], [@2022-12-29 | CT]; metabolic characterization via PET pending.  
- Bone metastasis suspected with new iliac lesion [@2022-12-29 | MR]; consider skeletal-targeted agents per guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42].  
- Splenic hypodensity indeterminate for metastasis [@2022-12-29 | CT]; recommend FDG-PET to clarify metabolic activity.
  
  *(2026-01-21T08:33:12.199946)*


### assistant
- **User:** Summarize expert opinions concisely for MDT.
{"chair":"Additionally","oncologist":"- Recurrent clear cell carcinoma with rising CA125/CA19-9; imaging confirms liver and bone metastases [@2022-12-29 | CT].  \n- BRCA1/2 and HRD negative per comprehensive NGS; molecular profile supports non-homologous recombination repair deficiency [@OH2203828 | Genomics].  \n- Current anemia (HGB 74 g/L) requires evaluation; recent labs confirm stable renal/hepatic function [@20230103|5600862 | LAB].","radiologist":"- Presacral mass increased to 53×44 mm with heterogeneous enhancement and new right iliac bone nodule [@2022-12-29 | MR]  \n- Multiple hepatic metastases progressed in size and number; splenic hypodensity suggests possible infarct [@2022-12-29 | CT]  \n- Peritoneal and sacral involvement noted; surveillance imaging supports disease progression [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]","pathologist":"- Ovarian origin favored: PAX8+, HNF1B+, WT1–, NapsinA focal+ supports clear cell carcinoma [@OH2203828 | Genomics]  \n- BRCA1/2 and HRD status negative per comprehensive NGS [@OH2203828 | Genomics]  \n- Molecular tumor profiling recommended to guide therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]","nuclear":"Unknown/needs update."}

Output:
Key Knowledge:
- ...
Controversies:
- ...
Missing Info:
- ...
Working Plan:
- ...
  
  **Assistant:** **Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.
  
  *(2026-01-21T08:32:20.459587)*

- **User:** You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.

CURRENT_MDT_GLOBAL_KNOWLEDGE:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising tumor markers (CA125/CA19-9).  
- Imaging demonstrates progressive disease: enlarged presacral mass (53×44 mm), new right iliac bone nodule, multiple progressive hepatic metastases, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; molecular profile indicates non-homologous recombination deficiency (NGS: OH2203828).  
- Current anemia (HGB 74 g/L); renal and hepatic function stable.  

**Controversies:**  
- Optimal systemic therapy in HRD-negative recurrent clear cell carcinoma with limited chemosensitivity; role of immunotherapy or targeted agents remains uncertain.  
- Clinical significance of splenic hypodensity (possible infarct vs. metastasis) requires clarification.  

**Missing Info:**  
- Nuclear medicine findings (e.g., PSMA/PET-CT or FDG-PET) pending/unknown.  
- Recent performance status, transfusion dependence, or symptom burden not provided.  
- Prior treatment history (e.g., platinum sensitivity, prior lines of therapy) not detailed.  

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and tumor markers.  
- Evaluate anemia (etiology and need for transfusion/intervention).  
- Pursue molecular tumor profiling to identify potential therapeutic targets.  
- Multidisciplinary discussion on systemic therapy options (e.g., platinum-based chemotherapy, clinical trials, immunotherapy consideration given histology and biomarker status).  
- Clarify splenic lesion with additional imaging if needed.

ROUND_1_FINAL_PLANS_JSON:
{"chair":"- Confirm progression in platinum-resistant ovarian clear cell carcinoma with rising CA125 [@2022-12-29 | LAB] and new metastases on [@2022-12-29 | MR], [@2022-12-29 | CT]  \n- Prioritize symptomatic and supportive management given HGB 74 g/L [@20230103|5600862 | LAB] before next systemic regimen  \n- Pursue FDG-PET or confirmatory imaging for indeterminate splenic lesion [@2022-12-29 | CT] per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13] for accurate staging","oncologist":"- Proceed with platinum-resistant recurrence regimen given HRD-negative status and progression within 6 months [@OH2203828 | Genomics; @guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13].  \n- Address symptomatic anemia (HGB 74 g/L) prior to systemic therapy; assess transfusion need [@20230103|5600862 | LAB].  \n- Obtain PET imaging to clarify splenic lesion and metastatic burden; guide skeletal protection if confirmed [@2022-12-29 | CT].","radiologist":"- Progressive presacral and new right iliac bone lesions confirmed on MRI [@2022-12-29 | MR]  \n- Hepatic metastases increased in number and size; splenic hypodensity requires PET correlation [@2022-12-29 | CT]  \n- Disease progression evident; consider staging with FDG-PET per NCCN guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]","pathologist":"- Recurrent clear cell carcinoma confirmed: PAX8+, HNF1B+, WT1– [@OH2203828 | Genomics]  \n- BRCA1/2 and HRD negative; consider non-platinum regimens or trials [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 13]  \n- FOLR1, TMB, and PD-L1 status unknown; pending update from tissue profiling [@OH2203828 | Genomics]","nuclear":"- Progressive presacral and hepatic metastases confirmed on recent MR/CT [@2022-12-29 | MR], [@2022-12-29 | CT]; metabolic characterization via PET pending.  \n- Bone metastasis suspected with new iliac lesion [@2022-12-29 | MR]; consider skeletal-targeted agents per guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 42].  \n- Splenic hypodensity indeterminate for metastasis [@2022-12-29 | CT]; recommend FDG-PET to clarify metabolic activity."}
  
  **Assistant:** **Key Knowledge:**  
- Recurrent clear cell ovarian carcinoma confirmed (PAX8+, HNF1B+, WT1–, NapsinA focal+) with rising CA125/CA19-9.  
- Progressive disease: enlarging presacral mass (53×44 mm), new right iliac bone metastasis, multiple progressing hepatic lesions, peritoneal and sacral involvement.  
- BRCA1/2 and HRD negative; classified as platinum-resistant recurrence (progression within 6 months).  
- Anemia present (HGB 74 g/L); stable renal/hepatic function; symptomatic management prioritized prior to next-line therapy.  
- Splenic hypodensity noted on CT; metabolic characterization pending to rule out metastasis.  
- FDG-PET recommended for accurate staging and assessment of metabolic burden.

**Controversies:**  
- Optimal systemic regimen in HRD-negative, platinum-resistant clear cell carcinoma with limited response to standard chemotherapy; role of non-platinum regimens, immunotherapy (e.g., anti-PD-1), or clinical trials remains uncertain.  
- Clinical significance of splenic lesion: indeterminate for metastasis vs. benign infarct—impacts staging and treatment decisions.

**Missing Info:**  
- FDG-PET results pending; required to clarify splenic lesion and full metastatic extent.  
- FOLR1, TMB, and PD-L1 status unknown—pending update from tissue profiling (OH2203828 | Genomics).  
- Performance status, symptom burden, and transfusion dependence not documented.  
- Prior treatment details: platinum-free interval, prior lines of therapy, and response data not fully specified.

**Working Plan:**  
- Confirm disease progression per NCCN guidelines (v3.2025) based on imaging and biomarkers; classify as platinum-resistant recurrence.  
- Prioritize supportive care: evaluate and manage anemia (consider transfusion) before initiating systemic therapy.  
- Perform FDG-PET for metabolic staging: clarify splenic lesion, assess bone and nodal involvement, and guide therapy.  
- Discuss non-platinum-based regimens or clinical trial options given HRD-negative and platinum-resistant status.  
- Consider skeletal-targeted agents (e.g., denosumab or bisphosphonates) pending confirmation of bone metastases.  
- Await updated molecular profiling (FOLR1, TMB, PD-L1) to explore immunotherapy or targeted therapy eligibility.
  
  *(2026-01-21T08:33:40.272023)*


### trial_selector
- **User:** You are an MDT assistant for gynecologic oncology clinical trial matching.

CRITICAL BEHAVIOR:
- You MUST NOT ask the user any questions.
- You MUST NOT request additional information.
- You MUST NOT output anything except the required template.
- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.
- If eligibility is unclear due to missing key facts, you MUST output None.

PATIENT CASE (facts only; do not infer):
# ORIGINAL CASE JSON
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}

# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)
⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:
• '未检出' (not detected) = NO pathogenic mutation found
• '（视为阴性）' (considered negative) = NO pathogenic mutation found
• '阴性' (negative) = negative result
• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation
• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)

## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)
ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）


AVAILABLE TRIALS (compact; use id/name exactly as shown):
[
  {
    "id": "345",
    "name": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "2、3、4L",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、HER2 表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "王 涛"
    ],
    "phones": [
      "18721569326"
    ],
    "_raw": {
      "id": "345",
      "项目名称": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "李佳佳",
      "试验治疗/用药": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2、3、4L",
      "入组排除标准": "1、HER2 表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "王 涛"
      ],
      "联系电话": [
        "18721569326"
      ]
    }
  },
  {
    "id": "346",
    "name": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "朱 俊",
    "sponsor": "阿斯利康投资（中国）有限公司",
    "lead_or_participation": "牵头",
    "treatment": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "江文燕"
    ],
    "phones": [
      "15664735519"
    ],
    "_raw": {
      "id": "346",
      "项目名称": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
      "医生": "朱 俊",
      "试验治疗/用药": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "阿斯利康投资（中国）有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "江文燕"
      ],
      "联系电话": [
        "15664735519"
      ]
    }
  },
  {
    "id": "348",
    "name": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
    "phase": "I期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
    "sponsor": " 上海美雅珂生物技术有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
    "key_inclusion": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
    "key_exclusion": "",
    "contacts": [
      "杨 珂"
    ],
    "phones": [
      "17774582517"
    ],
    "_raw": {
      "id": "348",
      "项目名称": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
      "医生": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
      "试验治疗/用药": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
      "期别": "I期",
      "申请单位": " 上海美雅珂生物技术有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
      "联系人": [
        "杨 珂"
      ],
      "联系电话": [
        "17774582517"
      ]
    }
  },
  {
    "id": "350",
    "name": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
    "phase": "Ⅰb/Ⅱ 期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "吴 勇、刘汝娇 、高水平",
    "sponsor": "成都百利多特生物药业有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "单臂研究\n\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
    "key_exclusion": "",
    "contacts": [
      "李 想"
    ],
    "phones": [
      "17703993082"
    ],
    "_raw": {
      "id": "350",
      "项目名称": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
      "医生": "吴 勇、刘汝娇 、高水平",
      "试验治疗/用药": "单臂研究<br />\r\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />",
      "期别": "Ⅰb/Ⅱ 期",
      "申请单位": "成都百利多特生物药业有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
      "联系人": [
        "李 想"
      ],
      "联系电话": [
        "17703993082"
      ]
    }
  },
  {
    "id": "351",
    "name": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳、刘汝娇",
    "sponsor": "西藏海思科制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
    "key_inclusion": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
    "key_exclusion": "",
    "contacts": [
      "张倩野"
    ],
    "phones": [
      "18627004197"
    ],
    "_raw": {
      "id": "351",
      "项目名称": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
      "医生": "李佳佳、刘汝娇",
      "试验治疗/用药": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
      "期别": "Ⅰ期",
      "申请单位": "西藏海思科制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
      "联系人": [
        "张倩野"
      ],
      "联系电话": [
        "18627004197"
      ]
    }
  },
  {
    "id": "353",
    "name": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "刘汝娇",
    "sponsor": " 石药集团中奇制药技术（石家庄）有限公司",
    "lead_or_participation": "参与（天津市肿瘤医院 郝继辉）",
    "treatment": "注射用西罗莫司（白蛋白结合型）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "刘 涵"
    ],
    "phones": [
      "19109628595"
    ],
    "_raw": {
      "id": "353",
      "项目名称": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
      "医生": "刘汝娇",
      "试验治疗/用药": "注射用西罗莫司（白蛋白结合型）",
      "期别": "Ⅰ期",
      "申请单位": " 石药集团中奇制药技术（石家庄）有限公司",
      "牵头/参与": "参与（天津市肿瘤医院 郝继辉）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "刘 涵"
      ],
      "联系电话": [
        "19109628595"
      ]
    }
  },
  {
    "id": "354",
    "name": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "吴 勇",
    "sponsor": " 浙江道尔生物科技有限公司",
    "lead_or_participation": "参与（组长单位：上海市肺科医院）",
    "treatment": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
    "key_inclusion": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\n\n2、HPV 16+",
    "key_exclusion": "",
    "contacts": [
      "浦东/郭 伟 、徐汇/江文艳"
    ],
    "phones": [
      "13156793722、15664735519"
    ],
    "_raw": {
      "id": "354",
      "项目名称": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
      "医生": "吴 勇",
      "试验治疗/用药": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
      "期别": "Ⅰ期",
      "申请单位": " 浙江道尔生物科技有限公司",
      "牵头/参与": "参与（组长单位：上海市肺科医院）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\r\n2、HPV 16+<br />",
      "联系人": [
        "浦东/郭 伟 、徐汇/江文艳"
      ],
      "联系电话": [
        "13156793722、15664735519"
      ]
    }
  },
  {
    "id": "358",
    "name": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "2-3线",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "徐汇/牛紫嫣 浦东/刘雅琦"
    ],
    "phones": [
      "15638299516 18636833967 "
    ],
    "_raw": {
      "id": "358",
      "项目名称": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "张 剑 、李佳佳",
      "试验治疗/用药": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
      "期别": "Ⅰ期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2-3线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "徐汇/牛紫嫣 浦东/刘雅琦"
      ],
      "联系电话": [
        "15638299516 18636833967 "
      ]
    }
  },
  {
    "id": "359",
    "name": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": ">2L",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳 、刘汝娇、 高水平",
    "sponsor": "苏州盛迪亚生物医药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、组织学确诊的子宫颈癌；\n\n2、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "黄洋洋"
    ],
    "phones": [
      "13226861415"
    ],
    "_raw": {
      "id": "359",
      "项目名称": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
      "医生": "张 剑 、李佳佳 、刘汝娇、 高水平",
      "试验治疗/用药": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "Ⅰ期",
      "申请单位": "苏州盛迪亚生物医药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": ">2L",
      "入组排除标准": "1、组织学确诊的子宫颈癌；<br />\r\n2、标准治疗失败或无标准治疗患者<br />",
      "联系人": [
        "黄洋洋"
      ],
      "联系电话": [
        "13226861415"
      ]
    }
  },
  {
    "id": "361",
    "name": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "Bayer Consumer Care AG",
    "lead_or_participation": "参与",
    "treatment": "单臂研究\n\nBAY 2927088（TKI，靶向HER2）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者；\n\n2、HER2激活突变（本院或认证的机构）；\n\n3、需提供肿瘤组织切片。",
    "key_exclusion": "",
    "contacts": [
      "李金山"
    ],
    "phones": [
      "18893190113 "
    ],
    "_raw": {
      "id": "361",
      "项目名称": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
      "医生": "李佳佳",
      "试验治疗/用药": "单臂研究<br />\r\nBAY 2927088（TKI，靶向HER2）<br />",
      "期别": "II期",
      "申请单位": "Bayer Consumer Care AG",
      "牵头/参与": "参与",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者；<br />\r\n2、HER2激活突变（本院或认证的机构）；<br />\r\n3、需提供肿瘤组织切片。<br />",
      "联系人": [
        "李金山"
      ],
      "联系电话": [
        "18893190113 "
      ]
    }
  }
]

DECISION RULE (be conservative):
Recommend ONE trial ONLY IF ALL are true:
1) Cancer type / primary site clearly matches.
2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).
3) Required biomarker/subtype is explicitly present in case text (if trial requires it).
4) No more than 2 critical eligibility confirmations remain.

If ANY of the above is not satisfied -> output None.

OUTPUT TEMPLATE (EXACT; no extra text):

Trial Recommendation:
- id: <trial id or None>
- name: <trial name or None>
- Reason: <1 short sentence>
- Missing eligibility confirmations (0-2 items):
  - item1 (or "None")
  - item2
  
  **Assistant:** Trial Recommendation:
- id: None
- name: None
- Reason: HER2 status is unknown and required for all potentially applicable trials.
- Missing eligibility confirmations (0-2 items):
  - HER2 expression status (IHC or mutation)
  - Confirmation of treatment line beyond platinum resistance
  
  *(2026-01-21T08:33:42.143930)*

